Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XBB.1.5 vaccine
- Development stage
- Approved
- Lead developer
- Siam Commercial Bank
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
The XBB.1.5 vaccine is a type of vaccine developed to target the SARS-CoV-2 Omicron XBB.1.5 variant. It is available in various platforms, including mRNA-based, protein-based (e.g., Nuvaxovid), and inactivated vaccine formulations. The vaccine works by eliciting an immune response, primarily through the production of neutralizing antibodies and T-cell responses, against the spike protein of the XBB.1.5 variant. It is intended to prevent or mitigate COVID-19, particularly in the context of evolving SARS-CoV-2 variants. Studies have evaluated its immunogenicity, safety, and effectiveness in diverse populations, including older adults and immunocompromised individuals.
- Brand names
- Nuvaxovid
- Other names
- monovalent Omicron XBB.1.5 vaccinemonovalent XBB.1.5 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on XBB.1.5 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XBB.1.5 vaccine.